{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:58:00Z","timestamp":1775843880483,"version":"3.50.1"},"reference-count":13,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) were historically considered contraindicated in severe aortic stenosis (AS) due to theoretical haemodynamic risks. Contemporary evidence increasingly challenges this paradigm, yet data on preoperative use and postoperative outcomes remain limited. We examined the association between preoperative ACEi\/ARB use and mortality following aortic valve replacement. Methods: We conducted a retrospective cohort study of 198 consecutive patients undergoing transcatheter (TAVI) or surgical aortic valve replacement (SAVR) at a single tertiary centre between May 2020 and March 2025. Complete one-year follow up was available for 185 patients (93%). The primary outcome was one-year all-cause mortality. Multivariable logistic regression adjusted for age, sex, hypertension, diabetes, LVEF, and procedure type. Results: Of 198 patients, 80 (40%) were receiving ACEi\/ARB therapy preoperatively. ACEi\/ARB users had a higher prevalence of hypertension (82% vs. 53%, p &lt; 0.001) and diabetes (48% vs. 27%, p = 0.005) but similar age, valve area, and ejection fraction. Unadjusted one-year mortality was lower in the ACEi\/ARB group (7% vs. 19%; odds ratio [OR] 0.33, 95% CI 0.12\u20130.91, p = 0.030). After multivariable adjustment for confounders including age, diabetes, and hypertension, the association did not reach statistical significance (adjusted OR 0.33, 95% CI 0.10\u20131.12, p = 0.075). Among diabetic patients, unadjusted one-year mortality was numerically lower in the ACEi\/ARB group (12% vs. 35%, p = 0.038); however, six subgroup comparisons were performed and this result would not survive Bonferroni correction (threshold p &lt; 0.008). This exploratory finding should be interpreted with caution given the small sample size and absence of adjustment for confounders. Conclusions: Preoperative ACEi\/ARB use was associated with lower unadjusted one-year mortality, but this association did not reach statistical significance after multivariable adjustment and residual confounding cannot be excluded. ACEi\/ARB use was not associated with increased mortality in this cohort. These hypothesis-generating findings from a single-centre observational study require confirmation in adequately powered prospective trials.<\/jats:p>","DOI":"10.3390\/jcm15082904","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:05:51Z","timestamp":1775840751000},"page":"2904","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Undergoing Aortic Valve Replacement for Severe Aortic Stenosis: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Husnain","family":"Abid","sequence":"first","affiliation":[{"name":"Midland Metropolitan University Hospital, Sandwell and West Birmingham NHS Trust, Birmingham B66 2QT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0495-9773","authenticated-orcid":false,"given":"Yusuf","family":"Khan","sequence":"additional","affiliation":[{"name":"Midland Metropolitan University Hospital, Sandwell and West Birmingham NHS Trust, Birmingham B66 2QT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-7390","authenticated-orcid":false,"given":"Nazish","family":"Khan","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham B15 2TH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawad","family":"Khan","sequence":"additional","affiliation":[{"name":"Midland Metropolitan University Hospital, Sandwell and West Birmingham NHS Trust, Birmingham B66 2QT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5687-2535","authenticated-orcid":false,"given":"Richard Paul","family":"Steeds","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham B15 2TH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/108155890405200334","article-title":"Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function","volume":"52","author":"Zhao","year":"2004","journal-title":"J. Investig. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.jhh.1001260","article-title":"ACE inhibition in aortic stenosis: Dangerous medicine or golden opportunity?","volume":"15","author":"Routledge","year":"2001","journal-title":"J. Hum. Hypertens."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.jacc.2012.02.093","article-title":"Calcific aortic stenosis: A disease of the valve and the myocardium","volume":"60","author":"Dweck","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jcmg.2016.10.007","article-title":"Myocardial fibrosis and cardiac decompensation in aortic stenosis","volume":"10","author":"Chin","year":"2017","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/ehjci\/jev043","article-title":"A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial)","volume":"16","author":"Bull","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jacc.2011.01.063","article-title":"Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis","volume":"58","author":"Nadir","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.2018.18077","article-title":"Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement","volume":"320","author":"Inohara","year":"2018","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/eurheartj\/ehz769","article-title":"Impact of renin-angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: An analysis from the PARTNER 2 trial and registries","volume":"41","author":"Chen","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Guan, Y., Kong, X., Zhu, H., Li, H., Zhao, L., Guo, F., and Lv, Q. (2023). Association of renin-angiotensin system inhibitors use with short- and long-term mortality in patients with aortic stenosis: A systematic review and meta-analysis. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.917064"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/01.CIR.90.6.2761","article-title":"Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis","volume":"90","author":"Friedrich","year":"1994","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1161\/01.CIR.0000035655.45453.D2","article-title":"Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma","volume":"106","author":"Shavelle","year":"2002","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_13","first-page":"e72","article-title":"2020 ACC\/AHA Guideline for the management of patients with valvular heart disease","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/2904\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:09:46Z","timestamp":1775840986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/2904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":13,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15082904"],"URL":"https:\/\/doi.org\/10.3390\/jcm15082904","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]}}}